chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Both my husband and I had a slight metallic taste after both shots; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 05Feb2021 13:00 (Lot number: EN 5318) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose number=1, product=COVID 19, brand=Pfizer, lot number=EL1283, lot unknown=False, administration date=08Jan2021, administration time=10:30 AM, vaccine location=Right arm,), administration date: 08Jan2021, for Covid 19 Immunization. The following information was reported: DYSGEUSIA (non-serious) with onset 05Feb2021 13:15, outcome "recovered" (2021), described as "Both my husband and I had a slight metallic taste after both shots". Therapeutic measures were not taken as a result of dysgeusia.  Additional Information: Other vaccine in four weeks: No, Covid prior vaccination: No, Covid tested post vaccination: No  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021251310 Same product and event, different patient
lt arm w/discoloration (old bruise) & small area of induration-not hot, no drainage, no red streaks, not painful pt states is resolving;
pt came into office 5 days post inject reporting several days of inc pain, swelling, redness @ site; objective findings were a 15 cm area of firm SC; tx w/ meds;
Rash on chest, arms, thighs. He also had swelling in right arm the day after immunization.
p/vax pt had severe h/a & neck pain, no fever, required adm for pain management & further observation;improved by 3rd day w/narcotic IV pain control then devel a lumbar puncture h/a;
When bandage taken off in the evening there was black material on the arm (did not look like dried blood). The arm has been painful for > 2 months. There is weakness at the site, aching and burning sensation like pins and needles sticking in arm (still happening as of 12/28/2018). The site oozes at times and was last noticed bleeding 12/7/2018 (shot was given 10/12/18).
Patient opted not to continue with vaccine series; Case reference number US-BN-2021-002434 is a spontaneous case report initially received from other health professional via regulatory authority (reference ID: USBAV21-0582) on 16-Nov-2021 and concerns a 25-year-old female patient.  The patient's medical history was not provided.  *The patient's concomitant medication included Liletta (levonorgestrel).*  On 08-Nov-2021, the patient was vaccinated with the first dose of RabAvert (inactivated rabies virus vaccine; batch number: ARBA911C), at dose of 1 mL, administered intramuscularly, *in the right deltoid*, at unknown route of administration, for pre-exposure prophylaxis.  *As reported, on an unspecified day, the patient opted not to continue with vaccine series (explicitly coded as 'Incomplete course of vaccination').*   *The reporter confirmed that the patient did not experience any adverse event.*  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).   Follow up information was received from other health professional on 03-Dec-2021: New information included, date of birth and initials for patient, concomitant medication, anatomical location for vaccination, confirmation that the patient did not experience any adverse event.; Reporter's Comments: The 25-year-old female patient was vaccinated with the first dose of RabAvert for pre-exposure prophylaxis. As reported, on an unspecified date, the patient opted not to continue with vaccine series, which is considered as inappropriate schedule of product administration and therefore is listed per company convention. No associated adverse events have been reported. The patient's medical history was not provided. The patient's concomitant medication included Liletta (levonorgestrel). Inappropriate schedule of product administration is not related to RabAvert, but to a human action. This case is non-serious.; Sender's Comments: The 25-year-old female patient was vaccinated with the first dose of RabAvert for pre-exposure prophylaxis. As reported, on an unspecified date, the patient opted not to continue with vaccine series, which is considered as inappropriate schedule of product administration and therefore is listed per company convention. No associated adverse events have been reported. The patient's medical history was not provided. The patient's concomitant medication included Liletta (levonorgestrel). Inappropriate schedule of product administration is not related to RabAvert, but to a human action. This case is non-serious.
He was in his usual state of excellent health until yesterday.  He noticed a small blister over his left upper gum.  This burst and was clearly filled with blood.  Over the ensuing 24 hours, he has had multiple such blisters and came to the Emergency Room for fear of a reaction to the COVID vaccine that he had had 13 days ago.  This was Johnson and Johnson.  He had no major reactions to it.  On coming to the Emergency Room today, he noticed significant petechiae forming over the lower extremities as well as scattered petechiae forming elsewhere.  He presented to the Emergency Room and there was noted to have a CBC showing hematocrit of 51, 4000 platelets, and a white count of 7.7 with an unremarkable differential.  INR is 1.1.  D-dimer was 0.33.  Chemistries were limited, but were within normal limits.
has congestion; spring allergies; COPD; red around at the site; had a rash around her arm at the injection site; 10cm  pinpoint red around at the site,  a band around her arm; still warm to touch; had fever; felt ill,  not feeling good; achy; This case was reported by a nurse via call center representative and described the occurrence of feeling unwell in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included smallpox vaccine (had a small pox vaccine about 40 years ago 2 cm above where Shingrix was administered).   On 21st February 2020, the patient received the 1st dose of Shingrix. On 22nd February 2020, 1 days after receiving Shingrix, the patient experienced feeling unwell and general body pain. On 23rd February 2020, the patient experienced fever. On 24th February 2020, the patient experienced injection site rash, erythema, feeling of warmth and injection site erythema. On an unknown date, the patient experienced nasal congestion, allergy and chronic obstructive pulmonary disease. On an unknown date, the outcome of the feeling unwell, general body pain, fever, injection site rash, erythema, feeling of warmth, nasal congestion, allergy, injection site erythema and chronic obstructive pulmonary disease were unknown.   It was unknown if the reporter considered the feeling unwell, general body pain, fever, injection site rash, erythema, feeling of warmth, nasal congestion, allergy, injection site erythema and chronic obstructive pulmonary disease to be related to Shingrix.  Additional details were provided as follows: The reporter stated that, after vaccination, next day the patient felt ill not feeling good and achy. The second day after vaccination, had fever and on third day had had a rash around arm at the injection site. The reporter stated that, description of rash was 10 cm pinpoint red around at the site, a band around arm. The reporter stated that, the patient still had warm to touch and a shadow of the rash remains.  The patient had congestion with spring allergies that started after the vaccination, and had chronic obstructive pulmonary disease. The patient was seen last week in the office and again day before reporting. The reporter consented to follow up.
This spontaneous case was reported by a consumer and describes the occurrence of ARTHRITIS (ARTHRITIS IN HAND AND FEET) and PAIN IN EXTREMITY (SORE ARM) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease. No Medical History information was reported. In 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form. On an unknown date, the patient experienced ARTHRITIS (ARTHRITIS IN HAND AND FEET) and PAIN IN EXTREMITY (SORE ARM). At the time of the report, ARTHRITIS (ARTHRITIS IN HAND AND FEET) and PAIN IN EXTREMITY (SORE ARM) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No concomitant medication was provided. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. No treatment medication was provided. Company comment: This is a spontaneous case concerns 73-years-old male patient with no medical history reported, who experienced the unexpected non-serious AESI event of Arthritis and expected non serious event of pain in extremity which occurred on unspecified day after receiving the third dose of mRNA-1273 vaccine in Oct 2021 and non-company product ADALIMUMAB (HUMIRA). Patient was not hospitalized, and treatment details and concomitant medications was not provided. The co-suspect product ADALIMUMAB remains a confounder. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement. Sender's Comments: This is a spontaneous case concerns 73-years-old male patient with no medical history reported, who experienced the unexpected non-serious AESI event of Arthritis and expected non serious event of pain in extremity which occurred on unspecified day after receiving the third dose of mRNA-1273 vaccine in oct 2021 and non-company product ADALIMUMAB (HUMIRA). Patient was not hospitalized, and treatment details and concomitant medications was not provided. The co-suspect product ADALIMUMAB remains a confounder. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement.
This case was reported by a healthcare professional and described the occurrence of decreased therapeutic response in a male subject of unspecified age who was vaccinated with ENGERIX B (GlaxoSmithKline). On unspecified dates the subject received 1st dose, 2nd dose and 3rd dose of ENGERIX B (details unknown). On unspecified dates at an unknown time later, the subject received another complete 3-dose series of ENGERIX B; the 3rd dose was given on an unknown date in 2009 (details unknown). The subject experienced decreased therapeutic response. On an unknown date his titers were measured as less than 5 mIU/mL. There were no adverse events. No further information was provided.
1/21 vaccination.  About two hours later, I went back to work. Sat down for lunch and took a bite, bit my tongue and didn't feel anything, my tongue was completely numb. nurse referred me to the ER. I went to the ER, they took my vitals and watched over me for about an hour. They gave me a steroid shot in the R hip and a steroid packet to take.
I went for a regularly scheduled physical in November and my Prostate-specific antigen was 8.9. I was prescribed antibiotics to see whether this was due to an infection. I took the medication for 10 days. After the dosage was completed, I returned to my doctor who completed another blood panel which reflected that my PSA was 10.9. I was sent for an MRI which showed Lesions in prostate. A Biopsy was completed, and I received the diagnosis of Prostate Cancer.  After the diagnosis I was sent for a Pet Scan on February 23, 2023.  to see if it had spread but it had not. I am now completing hormone therapy and will complete radiation   I am radiation oncologist and medical oncologist. They are continuing to do blood test and I will be having those regularly. I was advised treatment could last for a couple of years.
feel so sick; This is a spontaneous report from a contactable consumer or other non-HCP (patient herself) via Pfizer sponsored program COVAX Support. A female patient of an unspecified age received BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number- UNKNOWN) via an unspecified route of administration on 30Jun2021 as dose 1, single for COVID-19 immunization. Patient medical history and concomitant medications were not reported. Patient took first dose of covax on 30Jun2021 had not done second dose because she stated it made her feel so sick on an unspecified date in 2021. Medical Information included customer and/or medical inquiry was not forwarded or referred to MI. The outcome of the event was unknown.   Information on the lot/batch number has been requested.
Multiple Subsegmental pulmonary emboli.  Treated with anticoagulation. Doing well.
A few minutes after the injection I felt paresthesias in the entire vaccinated  arm, weakness and tingling persisted in the forearm and hand for hours. Continues to persists to a lesser degree  a day later.
Large,  red lesion around the injection site.  Size approximately 2in x 2in.   Slightly swollen and warm to touch.
p/ pt recv vax approx 5 days later pt exp severe urticaria & hives.
General hives BENADRYL. Observed 90 minutes, hives diminishing. Referred to allergist for testing.
pt recvd vax & exp fever & back pains;back pains were worse @ noc;no further details are available;
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 18Apr2022 as dose 4 (booster), single (Lot number: FM9992) at the age of 55 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 27Feb2021 as dose 1, single (Lot number: 001A21A), in left arm, on 27Mar2021 as dose 2, single (Lot number: 003B21A), in left arm and on 07Sep2021 as dose 3 (booster), single (Lot number: 059E21A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Type 1 diabetes, heart disease" (unspecified if ongoing); "heart disease" (unspecified if ongoing). Concomitant medication(s) included: LANTUS; NOVOLOG; FARXIGA; FUROSEMIDE; ASPIRIN [ACETYLSALICYLIC ACID]; ELIQUIS; METOPROLOL; DIGESTZYMES; PROBIOTICS. The following information was reported: DRUG INEFFECTIVE (medically significant) with onset May2022, outcome "not recovered", COVID-19 (medically significant) with onset May2022, outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: positive test. Relapse of COVID symptoms and positive test. Biitter and metallic taste in mouth while taking medication. Therapeutic measures were taken as a result of drug ineffective, covid-19.
I had a mild reaction to the first shot as mild fever and some body aches.Then a few days later it started out as an upset stomach leading to constipation and then diarrhea at first.  Then it seemed to heighten the sensitivities I had to milk, gluten, corn and soy worse.  Before the vaccination I could drink  lactaid milk or eat lactaid ice cream but within a few mouthfulls of ice cream it would go straight through me.  After a while I became anxious of food because I wasn't sure what was causing the issues. I figured out it was the food I was sensitive to and avoided it, but I had lost about 20 pounds in the process. I went to my regular doctor and she prescribed a stool test which came back negative for most common tests. I just had a colonoscopy and endoscopy today 09/28/2021 and the results are pending.
During observation, member stated that she could not see and was getting hot. Started to talk and could not speak and her eyes began rolling to the back of her head. ADULT EMERGENCY CALLED.  Pt assisted to wheelchair, member still unresponsive, unable to talk, blinking her eyes with eyes rolling back. Placed on stretcher. BP 126/96 HR 100 SPO2 100. EMS arrived and transported patient to hospital for further eval.
This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a 15-year-old female patient who received RABAVERT. Concomitant products included fluoxetine. On 19th April 2018, the patient received the 3rd dose of RABAVERT. In  April 2018, less than a week after receiving RABAVERT, the patient experienced influenza-like symptoms and rash. On 20th April 2018, the patient experienced leg pain, pain localized, pain in hip and pruritus. In April 2018, the outcome of the influenza-like symptoms, leg pain, pain localized, pain in hip, pruritus and rash were recovered/resolved. The reporter considered the influenza-like symptoms, leg pain, pain localized, pain in hip, pruritus and rash to be related to RABAVERT. Additional details were reported as follows: This case was reported by the mother of the patient. The patient's concomitant medication included birth control. The day after vaccination, the patient experienced pain and itching on her right side, hip area and down her leg which lasted for about 2 days. During that time that patient developed rash on her hip area and thighs and had flu like symptoms. All the events resolved within 2 to 3 days after the vaccination. The reporter was unable to provide full demographics for prescriber.
Patient  received vaccination approximately at 10:45 am,  he had told immunizer he had felt nervous and had fainted previously with other vaccinations.  Patient was monitored after vaccination patient said he felt dizzy, approximately 11:15 am he feel forward from chair and was attended to by staff.  EMTs were called and patient was taken to hospital for observation.  After vaccination pt had blood pressure readings of 130/80 5 min after 150/80 15 minutes after his blood sugar readings reported by family member on scene were 325 the previous evening and 255 the morning before he came in.  EMTs took a blood sugar reading 365 upon their arrival.
I had my shot on the 10th and on the evening of the 17th I broke out in a rash around the injection point.  It was red, raised and itchy.  It is now the 21st of March and it still is itchy and a little red.   I have been putting hydrocortisone 1% cream on it 3 times a day, and taking benadryl 2-3 times a day.    I went to the doctor to advise.  My doctor was unavailable. I am concerned about taking the next shot on April 7th.  I need to be advised.
Information has been received from a registered nurse concerning a 5 year old male pt who was vaccinated with a first dose of MMR II. The date of vaccination and the lot number are unknown. The pt was concomitantly vaccinated with poliovirus and diptheria toxoid+pertussis+tetanus toxoid vaccines. The nurse reported that the pt developed "autism." According to the nurse, the pt's family "feels it is due to" MMR II. The parents felt the child became "developmentally delayed" post vaccination. Medical attention was sought. It was also reported that the parents believe in holistic medicine and did not want to fully immunize the child. The pt was undergoing "holistic treatment." Upon internal review "autism" was considered an other important medical event (OMIC). Additional info has been requested.
Headache, Arthralgia, Fever, NauseaVomiting, "chest discomfort" Narrative:  Other Relevant History:
pt recv vax; devel gen hives on feet and at inject site;also devel swelling on both feet as well as rash; md stated that rash noted in am p/ vax;tx w/ dph;
pt is enrolled in rabies research study;pt recv vax & devel hives, rash, dx immune complex rxn;
Felt fatigued and rundown two hours post-vaccine, The following day, I felt body aches and headaches. 5 days later, Wednesday evening, I developed a migraine that persisted for 24 hours. From about Wednesday night at 8pm till Thursday night at 10pm- after receiving medication and intervention from the local ER, I had a migraine at about a 6-8/10 on the pain scale.  After 10 different medications administered, the migraine let up enough that I was able to be released home.
Swelling at sight day after. A week after - swelling and small red lump at injection site. It?s about the size of the sticker they put on when you get the vaccine
area of swelling, erythema, induration, one inch by 2.5 inches from the injection site and downwards, noted 24 hours after injection; area of swelling, erythema, induration, one inch by 2.5 inches from the injection site and downwards, noted 24 hours after injection; area of swelling, erythema, induration, one inch by 2.5 inches from the injection site and downwards, noted 24 hours after injection; This is a spontaneous report from a non-contactable physician (patient). A 31-year-old female patient received BNT162B2 (lot number: e51685), via an unspecified route of administration in left arm on 22Dec2020 at single dose for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced area of swelling, erythema, induration, one inch by 2.5 inches from the injection site and downwards, noted 24 hours after injection in Dec2020. The outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Pt developed headaches, leg aches, right hand tiredness, chills, and aching all over.  Diagnosed with degenerative joint dx. The follow up received on 9/27/01 states fatigue, flu-like symptoms, bone pain persist. Symptoms worse in cold weather. Feels "like I'm 80 years old when I get up in the morning: none of these symptoms were presnt pre-vaccination.
On the next day my left arm was sore, I developed a rash ,hot to touch and itchy. I had a Televisit told it might be Cellulitis take Benadryl and prescribed a antibiotic. They recommended  a steroid explained to me it would counteractive the vaccine I declined.  My symptoms lasted in total 2 weeks.
Menveo where the powder was reconstituted with another diluent; Inappropriate dose of vaccine administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of wrong diluent used in a 16-year-old patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA956A, expiry date 30-JUL-2024) for prophylaxis.   On 26-SEP-2023, the patient received the 2nd dose of Menveo. On 26-SEP-2023, an unknown time after receiving Menveo, the patient experienced wrong diluent used (Verbatim: Menveo where the powder was reconstituted with another diluent) and inappropriate dose of vaccine administered (Verbatim: Inappropriate dose of vaccine administered).  The outcome of the wrong diluent used and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK receipt date: 27-SEP-2023 The pharmacist reported the patient was given a dose of Menveo where the powder was reconstituted with another diluent other than what comes with Menveo, which led to wrong solution used and inappropriate dose of vaccine administered. The reporter consented to follow up.
Patient developed diarrhea a few hours after his injections. He had 5 bowels on Wednesday and 2 or 3 on Thursday and also vomited Thursday evening. He was fussy and cried much more than usual. He is feeling better today, 5/14, and has had one normal bowel and one bout of diarrhea. 3 year old sister has no stomach symptoms and neither do adults.
About 16 hours after the vaccine I began to experience sweating along with fever and chills. Despite taking an ibuprofen 800 mg I experienced extreme muscle aches, joint pain, fever, chills, extreme migraine with loss of vision, nausea, and vomiting. These symptoms did not cease until Friday morning. Friday still experiencing disorientation, dizziness, fatigue, and nausea.